Prospects for the development of fungal vaccines.
In an era that emphasizes the term "cost-effective," vaccines are the ideal solution to preventing disease at a relatively low cost to society. Much of the previous emphasis has been on childhood scourges such as measles, mumps, rubella, poliomyelitis, and Haemophilus influenzae type b. The concept of vaccines for fungal diseases has had less impact because of the perceived limited problem. However, fungal diseases have become increasingly appreciated as serious medical problems that require recognition and aggressive management. The escalation in the incidence and prevalence of infection has prompted a renewed interest in vaccine development. Herein, I discuss the most recent developments in the search for vaccines to combat fungal infections. Investigators have discovered several inert substances from various fungi that can mediate protection in animal models. The next challenge will be to find the suitable mode of delivery for these immunogens.
Deepe
G S
GS
Division of Infectious Diseases, University of Cincinnati College of Medicine, Ohio 45267-0560, USA. deepegs@ucunix.san.uc.edu
D000276:Adjuvants, Immunologic; D000917:Antibody Formation; D001758:Blastomyces / Q000276:immunology; D002175:Candida / Q000276:immunology; D003455:Cryptococcus neoformans / Q000276:immunology; D005657:Fungal Vaccines / Q000276:immunology*; D006658:Histoplasma / Q000276:immunology; D006801:Humans; D007111:Immunity, Cellular; D007113:Immunity, Innate; D016867:Immunocompromised Host / Q000276:immunology; D009181:Mycoses / Q000453:epidemiology / Q000276:immunology* / Q000517:prevention & control*; D010228:Paracoccidioides / Q000276:immunology; D011010:Pneumocystis / Q000276:immunology; D014611:Vaccination / Q000379:methods*
D000276:Adjuvants, Immunologic; D005657:Fungal Vaccines